Phoenix Financial’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.11M Buy
253,976
+91,739
+57% +$2.4M 0.04% 125
2026
Q1
$4.55M Buy
162,237
+2,186
+1% +$58.2K 0.04% 125
2025
Q4
$3.98M Buy
160,051
+7,879
+5% +$199K 0.04% 145
2025
Q3
$3.88M Buy
152,172
+75,569
+99% +$1.87M 0.05% 152
2025
Q2
$1.86M Buy
76,603
+30,805
+67% +$718K 0.02% 190
2025
Q1
$1.16M Sell
45,798
-21,692
-32% -$568K 0.02% 207
2024
Q4
$1.79M Buy
67,490
+764
+1% +$20.7K 0.02% 191
2024
Q3
$1.93M Sell
66,726
-9,784
-13% -$285K 0.03% 188
2024
Q2
$2.13M Sell
76,510
-12,120
-14% -$334K 0.03% 179
2024
Q1
$2.46M Sell
88,630
-31,530
-26% -$875K 0.03% 177
2023
Q4
$3.89M Sell
120,160
-22,187
-16% -$671K 0.06% 136
2023
Q3
$4.67M Sell
142,347
-13,805
-9% -$488K 0.09% 110
2023
Q2
$5.69M Buy
156,152
+135,510
+656% +$5.27M 0.12% 90
2023
Q1
$844K Buy
20,642
+5,677
+38% +$245K 0.02% 196
2022
Q4
$767K Buy
+14,965
New +$717K 0.01% 203
2020
Q4
– Sell
-88,703
Closed -$2.88M – 412
2020
Q3
$2.88M Buy
88,703
+23,109
+35% +$810K 0.12% 125
2020
Q2
$1.92M Buy
65,594
+2,446
+4% +$83.1K 0.08% 169
2020
Q1
$1.9M Buy
+63,148
New +$2.15M 0.1% 157

Other funds holding PFE

Phoenix Financial's PFE Position: Q2 2026 in Review

Phoenix Financial increased its Pfizer (PFE) stake by 57% in Q2 2026, buying an estimated $2.4M and bringing the position to 253,976 shares worth $6.11M. The position accounts for 0.04% of the portfolio, ranked #125.

Phoenix Financial first reported a position in PFE in Q1 2020 and has held it in 18 quarters since. 2,841 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Phoenix Financial held 253,976 shares of Pfizer worth $6.11M as of Q2 2026.
  • Phoenix Financial bought 91,739 Pfizer shares in Q2 2026, an estimated $2.4M.
  • Pfizer made up 0.04% of Phoenix Financial's portfolio in Q2 2026, its #125 holding.
  • Phoenix Financial first reported a position in Pfizer in Q1 2020 and has held it in 18 quarters since.
  • 2,841 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Phoenix Financial's 13F filing for Q2 2026, filed 11 Aug 2026.